In another application in immune therapy, anti-PD-L1 VHH in combination with an anti-OX40 antibody were used to construct the bispecific antibody PD-L1/OX40, that had better antitumor effects than the anti-PD-L1 VHH alone, anti-OX40 antibody alone, or a combination therapy of anti-PD-L1 VHH plus anti-OX40 in colon cancer and lung cancer mice models (118). This evidence concerns the gene TNFRSF4 and lung carcinoma.